Lexicon Pharmaceuticals, Inc.LXRX is a biopharmaceutical company that could be an interesting play for investors. That is because, not only does the stock have decent short-term momentum, but it is seeing solid activity on the earnings estimate revision front as well.
These positive earnings estimate revisions suggest that analysts are becoming more optimistic on LXRX's earnings for the coming quarter and year. In fact, consensus estimates have moved sharply higher for both of these time frames over the past four weeks, suggesting that Lexicon could be a solid choice for investors.
Current Quarter Estimates for LXRX
In the past 30 days, one estimate has gone higher for Lexicon while none have gone lower in the same time period. The trend has been pretty favorable too, with estimates narrowing from 62 cents a share 30 days ago, to 44 today, a move of 29%.
Current Year Estimates for LXRX
Meanwhile, Lexicon's current year figures are also looking quite promising, with three estimates moving higher in the past month, compared to two lower. The consensus estimate trend has also seen a boost for this time frame, narrowing from $1.88 per share 30 days ago to $1.62 per share today, an increase of 13.8%.
Lexicon Pharmaceuticals, Inc. Price and Consensus
The stock has also started to move higher lately, adding 7.04% over the past four weeks, suggesting that investors are starting to take note of this impressive story. So, investors may definitely want to consider this Zacks Rank #3 (Hold) stock to profit in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here .
Will You Make a Fortune on the Shift to Electric Cars?
Here's another stock idea to consider. Much like petroleum 150 years ago, lithium power may soon shake the world, creating millionaires and reshaping geo-politics. Soon electric vehicles (EVs) may be cheaper than gas guzzlers. Some are already reaching 265 miles on a single charge.
With battery prices plummeting and charging stations set to multiply, one company stands out as the #1 stock to buy according to Zacks research.
It's not the one you think.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.